Calendar

Here, 24/7 Wall St. presents a calendar of a few of the biggest clinical trial and FDA updates to watch for in early 2020.
Chris Lange
Here, 24/7 Wall St. has included a calendar of a few of the biggest clinical trial and FDA updates to watch for going into 2020.
Chris Lange
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of December.
Chris Lange
With China and OPEC both getting partial resolutions, here is what investors, economists and analysts are all on the hunt for the rest of 2019. That is stocks to buy, some that could even double, and...
Jon C. Ogg
Abstracts have been released for the companies presenting at the American Association for Cancer Research annual meeting, and Wedbush has some ideas for what the big movers could be.
Chris Lange
It's the weekend, but 24/7 Wall St. wanted to show our readers, who may not be on our email list, what they may see each day and on the weekend.
Jon C. Ogg
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
Chris Lange
The investing community is preparing for waves of fourth-quarter corporate earnings reports. Some companies likely will post stellar earnings, but where things are looking rather shaky is what to...
Jon C. Ogg
Here, 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the first quarter of 2019.
Chris Lange
24/7 Wall St. takes a look at what is coming up in the FDA calendar regarding biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest of 2018.
Chris Lange
Here 24/7 Wall St. takes a look at a recent report by Canaccord Genuity regarding to biotech and pharmaceutical companies expecting updates to their drug pipeline or other major events for the rest...
Chris Lange
  This last week was a crazy end to the October selling craze being followed by a flood of stock buying this week prior to Friday’s major profit taking. Some of that buying is obviously...
Jon C. Ogg
24/7 Wall St. has come up with its own view on earnings season by sector, along with relative performance on the top exchange traded funds for those sectors.
Jon C. Ogg
Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the remainder of October.
Chris Lange
We wouldn't want our readers thinking we were just taking time off to sit in the sun or in the rain. Here are more than 25 issues concerning your money and interests.
Jon C. Ogg